A career can look like a collection of companies until the third one makes the pattern impossible to miss. Mark Brosso has spent more than 25 years returning to the same awkward fact: healthcare produces vast quantities of data, yet the person who needs an answer can still be left staring at incompatible files, inconsistent vocabularies, and an expensive queue of technical work.
His response has not been a single invention. It has been a sequence. Health Market Science organized and licensed data, software, and analytical services. Aileron Solutions linked separate medical and pharmacy claims while preserving a longitudinal view. PurpleLab, where Brosso is founder and chief executive, puts harmonized information behind a no-code interface. Each venture begins a little farther along the same road.
There is a pleasing lack of romance in the origin. In sales and marketing roles around life sciences, Brosso noticed a specific commercial question: could a data business count case volumes for surgeons and cardiologists? It was narrow enough to be useful and broad enough to reveal an industry. In 1999, he started Health Market Science as a one-person company.
A counting problem becomes a company
The turn of the millennium was not a forgiving moment to raise money for an untested data business. The dot-com crash had made investors allergic to optimism, especially the kind wearing a new logo. Brosso nevertheless took Health Market Science through multiple rounds of debt and equity financing. The company served pharmaceutical and biotech firms, medical-device makers, pharmacy chains, and pharmacy-benefit organizations. Its work sat where databases met the people making commercial decisions.
By 2004 and 2005, Health Market Science had appeared on the Inc. 500 in consecutive years. In 2007, the company was purchased at an enterprise value of $55 million. Those figures make a tidy founder story. The more consequential result was less cinematic: Brosso had learned that organizing data could be a durable business, and that every solved data problem exposed another one behind it.
His second company, Aileron Solutions, went after the joining problem. It became, according to his PurpleLab biography, the first data aggregator to use the Universal Patient Key de-identification approach to connect disparate medical and pharmacy claims while maintaining the sequence of events over time. IMS Health, now IQVIA, bought Aileron in 2014.
Many founders spend an exit trying to become someone new. Brosso kept the problem and changed the level of attack. There is something almost comic in that loyalty. Healthcare data kept arriving in more places, under more labels, with more promises attached. He kept asking whether the person at the end of the chain could understand it before the opportunity to act had passed.
PurpleLab hides the plumbing, not the rigor
PurpleLab was founded in 2017. Its premise can be expressed with a deceptively friendly phrase: no code. A life-sciences, payer, provider, or advertising team should be able to frame a question and explore claims data without first assembling a small republic of database specialists. The simple interface, however, is merely the front door. Behind it sits the stubborn labor of organizing, cleansing, governing, and aligning information created for different purposes.
Brosso has called the vocabulary work a “Rosetta Stone-like” view. One dataset may describe an encounter one way and another may encode it differently. Neither is useful simply because it exists. PurpleLab builds the crosswalks that allow those records to participate in one coherent analysis. It is translation as infrastructure.
Even the company name carries the argument. In recruiting folklore, a “purple squirrel” is the rare candidate whose skills match an implausibly precise wish list. PurpleLab adopted the phrase for a combination its customers would otherwise have to assemble: deep data, flexible tools, and people who know how to apply both. The lab half of the name is equally deliberate. It suggests a place where questions are tested rather than answers merely retrieved. Together, the words make an unusual promise for an enterprise-software company. The product is not supposed to be a sealed oracle. It is supposed to be a working bench where a user can examine a market, compare cohorts, follow patterns, and revise the question without commissioning a new technical project each time.
This distinction between access and interpretation is Brosso’s recurring theme. Owning a library does not make one well read. In the same fashion, accumulating files does not produce evidence. PurpleLab’s product attempts to compress the journey between possession and comprehension, while keeping enough context intact for the answer to deserve trust.
The market rewarded that proposition. PurpleLab completed a Series A in 2019. By the time it announced a $40 million Series B led by Primus Capital in 2022, the company said it had recorded triple-digit growth for four consecutive years. The money was designated for new data assets, product development, and people. The company had also obtained Qualified Entity status from the Centers for Medicare and Medicaid Services, allowing access to Medicare claims for provider-performance evaluation.
A larger round for the interpretation layer
Ego gets a job description
Brosso’s most revealing public comments are not about databases. They are about the inner traffic of a founder’s mind. A chief executive can also be a shareholder, salesperson, product advocate, board member, and colleague. The same question may invite a different answer from every seat. His advice is to say which seat is speaking.
“As an entrepreneur, you have to be willing to suspend your personal goals and provide objective and fair responses in different roles,” he said in the 2023 Edison Partners conversation. Transparency about the frame, he continued, is essential. So is the willingness to inventory one’s strengths and weaknesses, then use the expertise of other people.
It is a practical philosophy for a repeat founder. The person whose conviction starts a company can become the person whose certainty slows it down. Role clarity gives conviction a boundary. It allows a founder to argue hard without pretending every argument carries the same institutional weight.
That interest extends beyond his own company. PurpleLab’s biography says helping founders and early-stage businesses is what gives him “the zoomies.” It describes him as an active investor, board director, and adviser. The phrase is cheerfully undignified, which may be its charm. Founders are routinely asked for a passion. Brosso’s official answer is, in effect, other founders.
The next layerA company that keeps widening the sentence
PurpleLab has continued to widen what sits on either side of its translation layer. It joined the Network Advertising Initiative in 2024 as its advertising work expanded, pairing audience and measurement tools with an explicit privacy framework. In early 2025, a partnership with Payerset joined claims information with pricing and coverage-policy records. The additions follow the old pattern: connect datasets that become more useful in one another’s company.
In September 2025, PurpleLab acquired KAID Health, whose technology applies artificial intelligence and natural-language processing to unstructured clinical narratives. Brosso described the combination as a move beyond traditional analytics. In plain terms, structured claims explain only part of an event. Narrative records contain another part. Bringing them together broadens the account a customer can examine.
There is a temptation to call this reinvention. It looks more like continuation. Health Market Science helped customers use organized databases. Aileron connected claims sources. PurpleLab made harmonized analysis available through software, then added pricing, coverage, advertising measurement, and unstructured text. The nouns change. The verb remains: translate.
Brosso’s stated objective is to get the right information to the right users at the right time, so risk becomes understandable and actionable. That sentence contains the quiet discipline of his career. Information must be right, but correctness alone is insufficient. It must arrive with an audience and a clock.
The founder’s first idea was to count something difficult to count. A quarter-century later, his companies have made the question larger without abandoning its shape. How do you take an untidy record of the world and turn it into a decision? Mark Brosso keeps building answers, one translation layer at a time.